Obesity, a chronic disease linked to increased risks of complications and mortality, has spurred significant research into the mechanisms of weight regulation and the gut-brain axis's role in appetite control. This understanding has paved the way for the development of safe and effective treatments, such as glucagon-like peptide-1 (GLP-1) receptor agonists, which are based on entero-pancreatic hormones. Additionally, several non-entero-pancreatic hormone therapies are under evaluation, offering alternative therapeutic options due to their distinct mechanisms of inducing weight loss. These emerging therapies highlight the expanding landscape of obesity treatment, aimed...
